cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate

Biotechnology and Bioengineering

Volumn 115, Issue 4, 2018, Pages 885-899

  Dey, Antu K ^a   Cupo, Albert ^b   Ozorowski, Gabriel ^c   Sharma, Vaneet K ^a   Behrens, Anna Janina ^d,e   Go, Eden P ^f   Ketas, Thomas J ^b   Yasmeen, Anila ^b   Klasse, Per J ^b   Sayeed, Eddy ^a   Desaire, Heather ^f   Crispin, Max ^d   Wilson, Ian A ^c   Sanders, Rogier W ^b,g   Hassell, Thomas ^a   Ward, Andrew B ^c   Moore, John P ^b  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY OF KANSAS   (United States)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

affinity purification; cGMP; HIV 1 vaccine; native like Env trimers; recombinant vaccine development; SOSIP

Indexed keywords

ANTIBODIES; CELL CULTURE; CHROMATOGRAPHIC ANALYSIS; COLUMN CHROMATOGRAPHY; COVALENT BONDS; GLYCOPROTEINS; PURIFICATION; RESEARCH LABORATORIES; SIZE EXCLUSION CHROMATOGRAPHY; SULFUR COMPOUNDS; VACCINES; VIRUSES;

AFFINITY PURIFICATION; CGMP; NATIVE-LIKE ENV TRIMERS; RECOMBINANT VACCINES; SOSIP;

OLIGOMERS;

BG 505SOSIP 664; CYCLIC GMP; FURIN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGENICITY; ARTICLE; CHO CELL LINE; DISULFIDE BOND; DRUG DESIGN; EXPRESSION VECTOR; GLYCOSYLATION; GOOD MANUFACTURING PRACTICE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PROCESS DEVELOPMENT; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; VIRAL CLEARANCE; ANIMAL; CRICETULUS; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROTEIN MULTIMERIZATION; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CHO CELLS; CRICETULUS; GLYCOSYLATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN MULTIMERIZATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 85042562900     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.26498     Document Type: Article

References (55)

1. Alam, S. M., Liao, H. X., Tomaras, G. D., Bonsignori, M., Tsao, C. Y., Hwang, K. K., … Haynes, B. F. (2013). Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. Journal of Virology, 87, 1554–1568.
2. Behrens, A. J., & Crispin, M. (2017). Structural principles controlling HIV envelope glycosylation. Current Opinion in Structural Biology, 44, 125–133.
3. Behrens, A. J., Vasiljevic, S., Pritchard, L. K., Harvey, D. J., Andev, R. S., Krumm, S. A., … Crispin, M. (2016). Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 Envelope glycoprotein. Cell Reports, 14, 2695–2706.
4. Blattner, C., Lee, J. H., Sliepen, K., Derking, R., Falkowska, E., de la Pena, A. T., … Ward, A. B. (2014). Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity, 40, 669–680.
5. Bleck, G. T. 2010. GPEx® A flexible method for the rapid generation of stable, high expressing, antibody producing mammalian cell lines. American Association of Pharmaceutical Scientists, 12.
6. Bleck, G. T. (2012). Consistent production of genetically stable mammalian cell lines. BioPharm International, 25, 56–59.
7. Cao, L., Diedrich, J. K., Kulp, D. W., Pauthner, M., He, L., Park, S. R., … Paulson, J. C. (2017). Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nature Communications, 8, 14954.
8. Cheng, C., Pancera, M., Bossert, A., Schmidt, S. D., Chen, R. E., Chen, X., … Mascola, J. R. (2015). Immunogenicity of a prefusion HIV-1 Envelope trimer in complex with a quaternary-structure-specific antibody. Journal of Virology, 90, 2740–2755.
9. Chuang, G. Y., Geng, H., Pancera, M., Xu, K., Cheng, C., Acharya, P., … Kwong, P. D. (2017). Structure-based design of a soluble prefusion-closed HIV-1 Env trimer with reduced CD4 affinity and improved immunogenicity. Journal of Virology, 91, e02268-16.
10. Chung, N. P., Matthews, K., Kim, H. J., Ketas, T. J., Golabek, M., de Los Reyes, K., … Cupo, A. (2014). Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. Retrovirology, 11, 33.
11. Coutu, M., & Finzi, A. (2015). HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. Journal of Virological Methods, 215–216, 37–44.
12. de Taeye, S. W., Ozorowski, G., Torrents de la Pena, A., Guttman, M., Julien, J. P., van den Kerkhof, T. L., … Sanders, R. W. (2015). Immunogenicity of stabilized HIV-1 Envelope trimers with reduced exposure of non-neutralizing epitopes. Cell, 163, 1702–1715.
13. Escolano, A., Dosenovic, P., & Nussenzweig, M. C. (2017). Progress toward active or passive HIV-1 vaccination. The Journal of Experimental Medicine, 214, 3–16.
14. Finzi, A., Pacheco, B., Zeng, X., Kwon, Y. D., Kwong, P. D., & Sodroski, J. (2010). Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. Journal of Virological Methods, 168, 155–161.
15. Go, E. P., Cupo, A., Ringe, R., Pugach, P., Moore, J. P., & Desaire, H. (2015). Native conformation and canonical disulfide bond formation are interlinked properties of HIV-1 Env glycoproteins. Journal of Virology, 90, 2884–2894.
16. Go, E. P., Ding, H., Zhang, S., Ringe, R. P., Nicely, N., Hua, D., … Desaire, H. (2017). Glycosylation benchmark profile for HIV-1 Envelope glycoprotein production based on eleven env trimers. Journal of Virology, 91, e02428–16.
17. Go, E. P., Hua, D., & Desaire, H. (2014). Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation. Journal of Proteome Research, 13, 4012–4027.
18. Go, E. P., Zhang, Y., Menon, S., & Desaire, H. (2011). Analysis of the disulfide bond arrangement of the HIV-1 envelope protein CON-S gp140 DeltaCFI shows variability in the V1 and V2 regions. Journal of Proteome Research, 10, 578–591.
19. Haynes, B. F., & Mascola, J. R. (2017). The quest for an antibody-based HIV vaccine. Immunological Reviews, 275, 5–10.
20. Huang, J., Kang, B. H., Pancera, M., Lee, J. H., Tong, T., Feng, Y., … Connors, M. (2014). Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature, 515, 138–142.
21. Joos, B., Trkola, A., Kuster, H., Aceto, L., Fischer, M., Stiegler, G., … Gunthard, H. F. (2006). Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrobial Agents and Chemotherapy, 50, 1773–1779.
22. Julien, J. P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., … Wilson, I. A. (2013). Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science, 342, 1477–1483.
23. Julien, J. P., Lee, J. H., Cupo, A., Murin, C. D., Derking, R., Hoffenberg, S., … Ward, A. B. (2013b). Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proceedings of the National Academy of Sciences of the United States of America, 110, 4351–4356.
24. Khayat, R., Lee, J. H., Julien, J. P., Cupo, A., Klasse, P. J., Sanders, R. W., … Ward, A. B. (2013). Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. Journal of Virology, 87, 9865–9872.
25. Klasse, P. J., Depetris, R. S., Pejchal, R., Julien, J. P., Khayat, R., Lee, J. H., … Moore, J. P. (2013). Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. Journal of Virology, 87, 9873–9885.
26. Klasse, P. J., LaBranche, C. C., Ketas, T. J., Ozorowski, G., Cupo, A., Pugach, P., … Moore, J. P. (2016). Sequential and simultaneous immunization of rabbits with HIV-1 Envelope glycoprotein SOSIP.664 trimers from clades A, B and C. PLoS Pathogens, 12, e1005864.
27. Korber, B., Hraber, P., Wagh, K., & Hahn, B. H. (2017). Polyvalent vaccine approaches to combat HIV-1 diversity. Immunological Reviews, 275, 230–244.
28. Lee, J. H., Andrabi, R., Su, C. Y., Yasmeen, A., Julien, J. P., Kong, L., … Ward, A. B. (2017). A broadly neutralizing antibody targets the dynamic HIV Envelope Trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity, 46, 690–702.
29. Lee, J. H., Leaman, D. P., Kim, A. S., Torrents de la Pena, A., Sliepen, K., Yasmeen, A., … Ward, A. B. (2015). Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. Nature Communications, 6, 8167.
30. Lyumkis, D., Julien, J. P., de Val, N., Cupo, A., Potter, C. S., Klasse, P. J., … Ward, A. B. (2013). Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science, 342, 1484–1490.
31. Medina-Ramirez, M., Garces, F., Escolano, A., Skog, P., de Taeye, S. W., Del Moral-Sanchez, I., … Sanders, R. W. (2017). Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. The Journal of Experimental Medicine, 214, 2573–2590.
32. Neville, D. C., Dwek, R. A., & Butters, T. D. (2009). Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. Journal of Proteome Research, 8, 681–687.
33. Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., … Kwong, P. D. (2014). Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 514, 455–461.
34. Pritchard, L. K., Vasiljevic, S., Ozorowski, G., Seabright, G. E., Cupo, A., Ringe, R., … Crispin, M. (2015). Structural constraints determine the glycosylation of HIV-1 Envelope trimers. Cell Reports, 11, 1604–1613.
35. Pugach, P., Ozorowski, G., Cupo, A., Ringe, R., Yasmeen, A., de Val, N., … Moore, J. P. (2015). A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene. Journal of Virology, 89, 3380–3395.
36. Ringe, R. P., Ozorowski, G., Rantalainen, K., Struwe, W. B., Matthews, K., Torres, J. L., … Moore, J. P. (2017). Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers. Journal of Virology, 91, e00677-17.
37. Ringe, R. P., Ozorowski, G., Yasmeen, A., Cupo, A., Cruz Portillo, V. M., Pugach, P., … Moore, J. P. (2017). Improving the expression and purification of soluble, recombinant native-like HIV-1 Envelope glycoprotein trimers by targeted sequence changes. Journal of Virology, 91, e00264-17.
38. Ringe, R. P., Yasmeen, A., Ozorowski, G., Go, E. P., Pritchard, L. K., Guttman, M., … Moore, J. P. (2015). Influences on the design and purification of soluble, recombinant native-like HIV-1 Envelope glycoprotein trimers. Journal of Virology, 89, 12189–12210.
39. Safrit, J. T., Fast, P. E., Gieber, L., Kuipers, H., Dean, H. J., & Koff, W. C. (2016). Status of vaccine research and development of vaccines for HIV-1. Vaccine, 34, 2921–2925.
40. Sanders, R. W., Derking, R., Cupo, A., Julien, J. P., Yasmeen, A., de Val, N., … Moore, J. P. (2013). A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathogens, 9, e1003618.
41. Sanders, R. W., & Moore, J. P. (2017). Native-like Env trimers as a platform for HIV-1 vaccine design. Immunological Reviews, 275, 161–182.
42. Sanders, R. W., van Gils, M. J., Derking, R., Sok, D., Ketas, T. J., Burger, J. A., … Moore, J. P. (2015). HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, aac4223.
43. Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y., … Nussenzweig, M. C. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 333, 1633–1637.
44. Stamatatos, L., Pancera, M., & McGuire, A. T. (2017). Germline-targeting immunogens. Immunological Reviews, 275, 203–216.
45. Torrents de la Pena, A., Julien, J. P., de Taeye, S. W., Garces, F., Guttman, M., Ozorowski, G., … Sanders, R. W. (2017). Improving the immunogenicity of native-like HIV-1 Envelope trimers by hyperstabilization. Cell Reports, 20, 1805–1817.
46. Trkola, A., Kuster, H., Rusert, P., von Wyl, V., Leemann, C., Weber, R., … Gunthard, H. F. (2008). In vivo efficacy of human immunodeficiency virus neutralizing antibodies: Estimates for protective titers. Journal of Virology, 82, 1591–1599.
47. Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan, N., … Katinger, H. (1996). Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology, 70, 1100–1108.
48. Verkerke, H. P., Williams, J. A., Guttman, M., Simonich, C. A., Liang, Y., Filipavicius, M., … Lee, K. K. (2016). Epitope-independent purification of native-like Envelope trimers from diverse HIV-1 isolates. Journal of Virology, 90, 9471–9482.
49. Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J. P., … Poignard, P. (2011). Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature, 477, 466–470.
50. Wang, Z., Lorin, C., Koutsoukos, M., Franco, D., Bayat, B., Zhang, Y., … Porter, F. (2016). Comprehensive characterization of reference standard lots of HIV-1 subtype C gp120 oroteins for clinical trials in southern African regions. Vaccines (Basel), 4, 17.
51. Ward, A. B., & Wilson, I. A. (2017). The HIV-1 envelope glycoprotein structure: Nailing down a moving target. Immunological Reviews, 275, 21–32.
52. Wieczorek, L., Krebs, S. J., Kalyanaraman, V., Whitney, S., Tovanabutra, S., Moscoso, C. G., … Polonis, V. R. (2015). Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 Envelope for use in preclinical and clinical vaccine research. Journal of Virology, 89, 7478–7493.
53. Yasmeen, A., Ringe, R., Derking, R., Cupo, A., Julien, J. P., Burton, D. R., … Klasse, P. J. (2014). Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology, 11, 41.
54. Yu, B., Fonseca, D. P., O'Rourke, S. M., & Berman, P. W. (2010). Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. Journal of Virology, 84, 1513–1526.
55. Zambonelli, C., Dey, A. K., Hilt, S., Stephenson, S., Go, E. P., Clark, D. F., … Barnett, S. W. (2016). Generation and characterization of a bivalent HIV-1 subtype C gp120 protein boost for proof-of-concept HIV vaccine efficacy trials in southern Africa. PLoS ONE, 11, e0157391.